GHRP-2: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 10 sources cited
Overview
GHRP-2 (Growth Hormone Releasing Peptide-2, pralmorelin) is a synthetic hexapeptide that potently stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the anterior pituitary. It is one of the most potent GHRPs available, producing robust GH pulses comparable to GHRH stimulation tests. GHRP-2 also stimulates appetite, with healthy men eating about 36% more at a buffet meal during infusion, raises ACTH and cortisol, and has shown cytoprotective effects in animal and cell studies.
Mechanism of Action
GHRP-2 binds to the growth hormone secretagogue receptor (GHS-R1a) on somatotroph cells in the anterior pituitary gland. This triggers intracellular calcium mobilization through the phospholipase C/IP3 pathway, resulting in GH vesicle exocytosis. Unlike GHRH, which amplifies existing GH pulses, GHRP-2 can initiate new GH release independently by acting through a completely separate receptor pathway. GHRP-2 also antagonizes somatostatin's inhibitory tone on GH release, meaning it works even when somatostatin levels are high (as occurs during aging). At the hypothalamic level, GHRP-2 stimulates GHRH-producing neurons and suppresses somatostatin-producing neurons, creating a dual amplification effect. GHRP-2 raises ACTH and cortisol where ipamorelin does not, and the effect is large enough that the GHRP-2 test is used in Japan to screen for secondary adrenal insufficiency, with an ACTH rise of about 1.55-fold separating an intact axis from pituitary failure.
GHRP-2 Benefits: What the Research Shows
- Bowers et al. (2004, Journal of Clinical Endocrinology and Metabolism) showed GHRP-2 given with GHRH drives GH secretion more than either peptide alone, with the acute synergy three times greater in young than older adults
- In the Japanese diagnostic test, a GH peak below 15 microg/l identifies GH deficiency, and healthy subjects respond to GHRP-2 regardless of sex, obesity or age
- GHRP-2 is used clinically in Japan as pralmorelin, developed by Kaken, as a diagnostic agent for hypothalamic-pituitary function
- A 48-week randomized trial of intranasal GHRP-2 in 126 GH-deficient children found no gain in height SD score or IGF-I over placebo, and development for short stature was discontinued
- GHRPs bind CD36 as well as GHS-R1a, and through CD36 they activate pro-survival signalling and reduce cell death in cardiac, neuronal, gastrointestinal and hepatic cells in preclinical models
- In a 30-day continuous subcutaneous infusion in older adults (Bowers et al., 2004, Journal of Clinical Endocrinology and Metabolism), GH secretion stayed above baseline throughout, rising more than 3-fold on day 1 and more than 1.8-fold on days 14 and 30, with IGF-I on a stable plateau
GHRP-2 Dosage
- Standard dose: 100–300 mcg subcutaneous injection, 2–3 times daily
- Optimal timing: upon waking (fasted), post-workout, and before bed for maximum GH pulse frequency
- Clinical diagnostic dose: 1 mcg/kg IV (used in GH stimulation testing)
- Saturation dose: approximately 100 mcg (1 mcg/kg for a 100 kg individual) — higher doses don't proportionally increase GH
- Cycle length: 8–12 weeks on, 4 weeks off to prevent desensitization
- Best results on an empty stomach — food (especially fats and carbohydrates) blunts GH response by 50–75%
- Often combined with a GHRH analog (CJC-1295) for synergistic GH amplification (3–5x greater response than either alone)
- Avoid within 2 hours of eating; wait at least 30 minutes after injection before consuming food
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
GHRP-2 Side Effects & Safety
Known Side Effects
- Increased appetite (ghrelin-mimetic effect) — healthy men ate about 36% more at a buffet meal while being infused with GHRP-2 than with saline
- ACTH and cortisol elevation — large enough to be used diagnostically: an ACTH rise of about 1.55-fold and peak cortisol around 10 to 12 microg/dl distinguish an intact pituitary-adrenal axis in the GHRP-2 test
- Mild prolactin increase — generally clinically insignificant but may be relevant for prolactin-sensitive individuals
- Water retention and mild bloating during the first 1–2 weeks
- Tingling or numbness in extremities (paresthesia) shortly after injection
- Occasional dizziness or lightheadedness, particularly when injecting in a fasted state
- Injection site reactions: redness, itching
Safety Profile
GHRP-2 has been given to healthy volunteers and patients in diagnostic testing in Japan, where it is used as a single dose rather than as ongoing treatment. In clinical studies at standard doses, serious adverse events are rare. The main concerns are its effects on cortisol and prolactin — while modest, chronic elevation of either hormone can have clinical consequences. Each dose raises ACTH and cortisol acutely, and in the 30-day continuous infusion study in older adults safety screening tests stayed normal, but no study has measured cortisol over longer use. Prolactin elevation is similarly transient but should be monitored in those with prolactinoma history. Individuals with diabetes should monitor blood glucose as GH can antagonize insulin action. Not recommended during active cancer (GH/IGF-1 may promote tumor growth). Contraindicated in pregnancy and breastfeeding. The longest published human exposure is 30 days of continuous infusion, and 48 weeks of intranasal dosing in children, so extended subcutaneous use is unstudied.
What to Expect
Week 1: Noticeable increase in appetite within hours of first injection. Improved sleep quality, especially when dosing before bed. Mild water retention and occasional tingling after injection. Week 2–4: Improved recovery from exercise, better sleep depth, skin quality begins to improve. Fat loss may begin, though appetite increase can offset this if diet is not controlled. Weeks 5–8: Measurable improvements in body composition (reduced fat, increased lean mass) especially when combined with resistance training. Hair and nail growth often accelerates. IGF-1 levels typically elevate 30–60% above baseline. Weeks 9–12: Peak benefits for body composition, recovery, and anti-aging markers. After cycling off, benefits gradually diminish over 2–4 weeks as GH patterns return to baseline.
Common Stacks
CJC-1295 (No DAC)
GHRH + GHRP synergy produces GH pulses 3–5x greater than either alone — the gold standard GH secretagogue stack
Ipamorelin
Some users alternate GHRP-2 (for potency) with Ipamorelin (for cleaner release) to balance efficacy and side effects
IGF-1 LR3
IGF-1 LR3 provides direct tissue-level anabolic signaling that complements GH-mediated systemic effects
Storage & Handling
Store lyophilized GHRP-2 at 2–8°C for up to 12 months or -20°C for longer storage. Reconstitute with bacteriostatic water (typically 1–2 mL per vial). Once reconstituted, refrigerate at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution. Protect from light. Solution should be clear and colorless.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Bowers CY, Granda R, Mohan S, et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004.
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004.
- Tanaka T, Hasegawa Y, Yokoya S, et al. Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency. Clin Pediatr Endocrinol. 2014.
- Laferrère B, Abraham C, Russell CD, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005.
- Suzuki S, Ruike Y, Ishiwata K, et al. Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. J Endocr Soc. 2022.
- Arimura H, Hashiguchi H, Yamamoto K, et al. Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure. Endocr J. 2016.
- Kimura T, Shimatsu A, Arimura H, et al. Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2. Endocr J. 2010.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008.
Related Peptides
Track GHRP-2 in Your Protocol
Log your GHRP-2 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free